Key Details
Annual EPS
-$5.32Annual ROE
-40.64%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 15, 2022Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with ADGI included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Adagio Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Adagio Therapeutics?
- What is the ticker symbol for Adagio Therapeutics?
- Does Adagio Therapeutics pay dividends?
- What sector is Adagio Therapeutics in?
- What industry is Adagio Therapeutics in?
- What country is Adagio Therapeutics based in?
- When did Adagio Therapeutics go public?
- Is Adagio Therapeutics in the S&P 500?
- Is Adagio Therapeutics in the NASDAQ 100?
- Is Adagio Therapeutics in the Dow Jones?
- When was Adagio Therapeutics's last earnings report?
- When does Adagio Therapeutics report earnings?
What is the primary business of Adagio Therapeutics?
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.
What is the ticker symbol for Adagio Therapeutics?
The ticker symbol for Adagio Therapeutics is NASDAQ:ADGI
Does Adagio Therapeutics pay dividends?
No, Adagio Therapeutics does not pay dividends
What sector is Adagio Therapeutics in?
Adagio Therapeutics is in the Healthcare sector
What industry is Adagio Therapeutics in?
Adagio Therapeutics is in the Biotechnology industry
What country is Adagio Therapeutics based in?
Adagio Therapeutics is headquartered in United States
When did Adagio Therapeutics go public?
Adagio Therapeutics's initial public offering (IPO) was on 06 August 2021
Is Adagio Therapeutics in the S&P 500?
No, Adagio Therapeutics is not included in the S&P 500 index
Is Adagio Therapeutics in the NASDAQ 100?
No, Adagio Therapeutics is not included in the NASDAQ 100 index
Is Adagio Therapeutics in the Dow Jones?
No, Adagio Therapeutics is not included in the Dow Jones index
When was Adagio Therapeutics's last earnings report?
Adagio Therapeutics's most recent earnings report was on 15 November 2022
When does Adagio Therapeutics report earnings?
The date for Adagio Therapeutics's next earnings report has not been announced yet